Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

758
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
758
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

915
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
915
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

529
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
529
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunization with cytoplasmic repetitive antigen and flagellar repetitive antigen of Trypanosoma cruzi stimulates a cellular immune response in mice.

Parasitology·2004
Same author

Effect of previous hormone replacement therapy on endometrial polyps during menopause.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2004
Same author

Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2004
Same author

Decreased humoral and pathologic responses in undernourished mice infected with Schistosoma mansoni.

Parasitology research·2004
Same author

Proliferation profile of endometrial polyps in post-menopausal women.

Maturitas·2001
Same author

Morphological aspects of Schistosoma mansoni adult worms isolated from nourished and undernourished mice: a comparative analysis by confocal laser scanning microscopy.

Memorias do Instituto Oswaldo Cruz·2001

Related Experiment Video

Updated: Feb 19, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K

GESTRINONE IN THE TREATMENT OF MYOMAS.

E M Coutinho1

  • 1From the Maternidade Climério de Oliveira Federal University of Bahia School of Medicine Salvador, Bahia, Brazil.

Acta Obstetricia Et Gynecologica Scandinavica
|November 11, 2017
PubMed
Summary

Gestrinone effectively reduces uterine myoma size in women, with tumor regression observed even after treatment cessation. This study explored its efficacy and side effects in over 300 patients.

Area of Science:

  • Reproductive Endocrinology
  • Gynecologic Oncology

Background:

  • Uterine myomas (fibroids) are common benign tumors affecting women of reproductive age.
  • Current treatments for uterine myomas have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy of gestrinone in inducing regression of uterine myomas.
  • To assess the impact of gestrinone treatment on myoma size and patient symptoms.

Main Methods:

  • A study involving over 300 women with uterine myomas.
  • Gestrinone administered orally or vaginally at doses of 2.5-5 mg, 2-3 times weekly.
  • Treatment duration varied from 6 months to 2 years based on uterine volume and myoma size.

Main Results:

Keywords:
Myomagestrinonetumor size

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

10.7K

Related Experiment Videos

Last Updated: Feb 19, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.6K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

10.7K
  • Significant reduction in uterine volume observed, particularly within the first 6 months of treatment.
  • Slower tumor regression rates noted after the initial 6 months.
  • Most patients experienced amenorrhea and alleviation of myoma-related symptoms like discomfort, dyspareunia, and dysuria.
  • Slow reactivation of tumor growth after treatment discontinuation in most cases.
  • Common reversible side effects included weight gain, seborrhea, and acne due to mild androgenicity.

    • Conclusions:

    • Gestrinone is effective in inducing uterine myoma regression and alleviating associated symptoms.
    • The drug demonstrates a favorable side effect profile, with most adverse events being reversible.
    • Gestrinone represents a potential therapeutic option for managing uterine myomas.